I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Angiologia
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
International Angiology 2006 June;25(2):169-74
Cost-effectiveness of Liple® (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument
Ikeda S. 1, Kobayashi M. 2, Fukuhara S. 3, Esato K. 4
1 Department of Pharmaceutical Sciences, School of Pharmacy, International University and Health Welfare, Otawara, Japan
2 Department of Nursing, School of Nursing and Rehabilitation Sciences, International University of Health and Welfare at Odawara, Odawara, Japan
3 Department of Clinical Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4 Yamaguchi Prefecture Central Hospital, Yamaguchi, Japan
Aim. This study was conducted to evaluate the health-related quality of life (HRQOL) and cost-effectiveness of LipoPGE1 when added to the conventional treatment of arteriosclerosis obliterans (ASO) patients. The research design consisted of a before and after-treatment study without comparison groups. We collected data from May 1999 through July 2001 at 473 institutions located throughout Japan. The subjects were ASO patients who experienced pain at rest or had ulcers of the extremities.
Methods. The observation period was a 2-month period that commenced with the start of administration of LipoPGE1. The HRQOL score (utility value) was obtained from the EQ-5D instrument, and the incremental cost-effectiveness ratio was calculated on the basis of quality-adjusted life years (QALYs).
Results. The mean utility value for the 2 months after the start of the administration of LipoPGE1 was 0.672, and it was a significantly higher (P<0.0001) than the 0.616 before administration of LipoPGE1. The incremental cost-effectiveness ratio was 18 807 US dollar/QALY assuming that drug efficacy persisted for 1 year after the end of LipoPGE1 therapy, and 75 227 dollar/QALY assuming a duration of just 3 months.
Conclusion. We concluded that when LipoPGE1 is added to the conventional treatment of ASO patients, the HRQOL of the patient improves, and it is highly cost-effective.